久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

  • AZ kicks off PhI trial of potential COVID-19 therapy pharmatimes
    August 26, 2020
    AstraZeneca has dosed the first participants in a Phase I trial of AZD7442, a combination of two monoclonal antibodies (mAbs) being developed for prevention and treatment of COVID-19.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service